ETC-216 - Phospholipid Therapy for Coronary Heart Disease (CHD) Patients

Print-Icon
Print

ETC-216 is a synthetic variant of high-density lipoprotein (HDL) and one of several HDL targeted therapies the company is developing for patients with CHD.
 
Next»

Return to Project




Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development